Oak Thistle LLC Acquires Shares of 7,359 Boston Scientific Corporation (NYSE:BSX)

Oak Thistle LLC bought a new stake in Boston Scientific Corporation (NYSE:BSX - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 7,359 shares of the medical equipment provider's stock, valued at approximately $742,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Bank Pictet & Cie Europe AG raised its holdings in shares of Boston Scientific by 40.8% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider's stock worth $6,529,000 after buying an additional 21,173 shares in the last quarter. Oppenheimer & Co. Inc. raised its holdings in shares of Boston Scientific by 18.8% during the 1st quarter. Oppenheimer & Co. Inc. now owns 39,523 shares of the medical equipment provider's stock worth $3,987,000 after buying an additional 6,264 shares in the last quarter. Segall Bryant & Hamill LLC acquired a new position in shares of Boston Scientific during the 1st quarter worth $8,234,000. Blue Trust Inc. raised its holdings in shares of Boston Scientific by 13.0% during the 1st quarter. Blue Trust Inc. now owns 5,000 shares of the medical equipment provider's stock worth $504,000 after buying an additional 575 shares in the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S raised its holdings in shares of Boston Scientific by 109.9% during the 4th quarter. BI Asset Management Fondsmaeglerselskab A S now owns 270,107 shares of the medical equipment provider's stock worth $24,126,000 after buying an additional 141,398 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Trading Up 0.3%

NYSE BSX traded up $0.37 during trading hours on Monday, hitting $106.51. 1,720,583 shares of the company's stock were exchanged, compared to its average volume of 7,702,616. The firm has a market cap of $157.57 billion, a price-to-earnings ratio of 63.31, a PEG ratio of 2.55 and a beta of 0.68. Boston Scientific Corporation has a 1-year low of $71.88 and a 1-year high of $108.94. The stock has a 50-day simple moving average of $103.58 and a 200 day simple moving average of $101.59. The company has a current ratio of 1.45, a quick ratio of 0.88 and a debt-to-equity ratio of 0.47.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. The business had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.39%. Boston Scientific's revenue was up 22.8% on a year-over-year basis. During the same period in the prior year, the firm earned $0.62 earnings per share. On average, equities analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insider Activity at Boston Scientific

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,314 shares of the firm's stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $102.06, for a total value of $1,767,066.84. Following the completion of the sale, the executive vice president owned 22,235 shares of the company's stock, valued at approximately $2,269,304.10. This trade represents a 43.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Michael F. Mahoney sold 164,443 shares of the firm's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $103.69, for a total value of $17,051,094.67. Following the completion of the sale, the chief executive officer directly owned 1,476,882 shares of the company's stock, valued at $153,137,894.58. This trade represents a 10.02% decrease in their position. The disclosure for this sale can be found here. Insiders sold 457,144 shares of company stock valued at $47,296,288 in the last ninety days. Insiders own 0.50% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on BSX shares. Evercore ISI boosted their price target on Boston Scientific from $110.00 to $112.00 and gave the stock an "outperform" rating in a report on Thursday, April 24th. Oppenheimer upped their target price on Boston Scientific from $110.00 to $118.00 and gave the stock a "market perform" rating in a report on Thursday. UBS Group upped their target price on Boston Scientific from $130.00 to $135.00 and gave the stock a "buy" rating in a report on Thursday. Barclays upped their target price on Boston Scientific from $125.00 to $133.00 and gave the stock an "overweight" rating in a report on Thursday. Finally, Citigroup reaffirmed a "buy" rating and issued a $125.00 target price (up previously from $119.00) on shares of Boston Scientific in a report on Thursday, May 22nd. Two equities research analysts have rated the stock with a hold rating, twenty-two have given a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $117.50.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.